EndeavorRx is an ADHD treatment for kids aged 8-12. It’s delivered through an immersive video game experience on mobile devices. Created by world-class neuroscientists and award-winning game designers, it targets areas of the brain that play a key role in attention function. As an FDA-authorized medical device, EndeavorRx must be prescribed by a healthcare professional. It should be considered for use as part of a therapeutic program.

The Propeller Digital Therapeutic Platform

Propeller’s FDA-cleared digital therapeutic platform consists of Bluetooth-enabled sensors, a digital patient experience through mobile app or web portal, a clinician insights portal for remote monitoring, plus tailored patient support through virtual coaching. These components seamlessly integrate with one another to improve health outcomes for patients, and in turn, drive measurable clinical and business outcomes for healthcare organizations. Here’s how it works:

1. PropellerConnect™ Sensors & Data Connectivity: Propeller sensors capture unique signals that passively record events, such as medication usage or respiration, and transmit data to Propeller via Bluetooth or hub connection. Sensors are compatible with more than 80% of inhaled medications on the U.S. market, including medications for MDI, Respimat®, Diskus®, Ellipta®, and Symbicort® inhalers.*
2. MyPropeller™ Patient App & Portal: Sensor data is sent to the Propeller mobile app or online portal, empowering patients to learn about their breathing and triggers while delivering personalized, motivating journeys that build healthy habits.
3. PropellerInsight™ Clinical Decision Support & Analytics: Via an EHR integration or our Clinician Portal, care teams can remotely monitor patients’ medication use and view on-demand reports to gain a clearer understanding of disease control status, symptoms, and triggers. These insights help inform clinical decisions and treatment plans, and enable proactive identification of patients who may be at a greater risk for an exacerbation and require timely clinical intervention.
4. PropellerCare™ Support and Coaching: Propeller’s patient success team ensures users receive personalized support and coaching to help them confidently navigate the platform, stay focused on their goals, and take control of their breathing.

Propeller Health Solutions

Propeller configures its digital therapeutic platform into a variety of solutions that help healthcare and life sciences organizations meet their goals while navigating the shift to value-based care.

• For Independent Physician Groups: Remote therapeutic monitoring programs to enhance care for eligible chronic patients
• For Hospitals and Health Systems: Digital health programs for select clinics, target populations, or systemwide; integration into a service line/specialty for population health management
• For Payers and Pharmacy Benefits Managers: Integration of digital health programs into existing care management or population health initiatives
• For Life Sciences Organizations: Integration or co-packaging of digital companion (i.e., sensor, app, support) with connected drug delivery devices such as inhalers to support clinical trials, medication adherence, and biologics

---

*Respimat is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc. Diskus and Ellipta are registered trademarks of the GlaxoSmithKline group of companies. Symbicort is a registered trademark of the AstraZeneca group of companies.

Propeller Health is a precision digital health company on a mission to uplift every person living with chronic disease so they can take control of their health and live a better life. We power motivating, care-connected patient journeys and unify value for all stakeholders – providers, health systems, payers, pharmaceutical companies, and other healthcare and life sciences organizations.

The Propeller Platform includes FDA-cleared and CE-marked medical devices, consumer apps, support, and secure access to clinical data for provider monitoring. Our precision approach motivates behavior change and tracks patient adherence that enables medication optimization, helping predict costly exacerbations. We set the scientific standard in digital-first chronic respiratory care through our peer-reviewed research demonstrating improved quality of life and clinical outcomes while lowering healthcare costs.

As a wholly owned subsidiary of ResMed, Propeller brings broad respiratory care expertise, digital therapeutic coverage, and scale globally.

It's time to change the way medicine is designed, delivered and experienced. At Akili, we believe effective medicine for serious illnesses can also be fun and engaging. We're creating a new class of digital medicines for people living with cognitive impairment, delivered through captivating video game experiences.

To learn about how Propeller differentiates from other options in this space, please reach out to info@propellerhealth.com. 

As a leading precision digital health company, Propeller Health differs from others in the industry in that:  

• Our 10+ FDA and CE cleared devices cover more than 80% of all inhaled medications on the market – and our capabilities go far beyond respiratory care.
• We have conducted 80+ commercial programs and research studies, and a body of research no other digital health company can match: more than 150 peer-reviewed publications and abstracts.
• Our parent company has decades of experience bringing specialized medical devices to market in more than 140 countries. Together, our regulatory expertise, logistics support, engineering and component sourcing knowledge is unmatched.
• We have unique experience partnering with and unifying value for stakeholders across the healthcare ecosystem: independent clinics, hospitals and health systems, payers and PBMs, pharmaceutical and life sciences companies, as well as patients and clinicians. 

---

Our FDA-cleared digital therapeutic platform stands apart from other digital health solutions in that: 

• It is used by a broad spectrum of patients from pediatric (asthma) to elderly (COPD), and is proven effective in engaging underserved and vulnerable patient populations (Medicaid, Medicare). 
• It engages patients with COPD — an often difficult to engage patient population — earlier in their care (stages 1 and 2). For patients whose conditions continue to progress, they can receive care in later stages (3 and 4) with solutions from our parent company, ResMed.